Inflammatory bowel disease (IBD) is a group of chronic conditions in which the immune system attacks the lining of the digestive tract, causing persistent inflammation, pain, and damage. An estimated 2.4 to 3.1 million people in the United States live with IBD, and while it can develop at any age, prevalence is highest among adults 45 and older. The two main forms are Crohn’s disease and ulcerative colitis, which differ in where and how deeply they affect the gut.
Crohn’s Disease vs. Ulcerative Colitis
Though both conditions cause chronic digestive inflammation, they behave differently in important ways. Ulcerative colitis is limited to the colon (large intestine). It typically starts in the rectum and spreads upward in a continuous line with no gaps. The inflammation stays shallow, affecting only the innermost lining of the colon wall.
Crohn’s disease can show up anywhere from the mouth to the anus, though it most commonly affects the end of the small intestine and the beginning of the colon. Unlike ulcerative colitis, Crohn’s often skips areas, leaving healthy patches of tissue between inflamed spots. It also digs deeper, potentially penetrating through all layers of the intestinal wall. That deeper damage is what makes Crohn’s more likely to cause complications like narrowing of the intestine, fistulas (abnormal tunnels between organs), and abscesses.
What Goes Wrong in the Immune System
Your gut is constantly exposed to bacteria, food particles, and other foreign substances. Normally, the immune system tolerates the trillions of harmless bacteria living in the intestines and responds only to genuine threats. In IBD, that tolerance breaks down. The balance between immune cells that promote inflammation and those that suppress it tips in the wrong direction, and the immune system begins reacting to the normal bacteria in your gut as if they were dangerous invaders.
This triggers an uncontrolled release of inflammatory signaling molecules that damage the intestinal lining. Once the lining is compromised, even more bacteria cross into the intestinal wall, fueling a cycle of inflammation that the body can’t shut off on its own. The result is the chronic, relapsing pattern that defines IBD: periods of active symptoms (flares) alternating with stretches of relative calm (remission).
Causes and Triggers
No single cause explains IBD. The current understanding is that genetically susceptible people develop the disease after environmental factors disrupt the balance of bacteria in their gut. This disruption, called dysbiosis, appears to be the spark that sets off the immune overreaction in people whose genetics make them vulnerable.
Several environmental factors are linked to that disruption. Antibiotic use can alter the composition of gut bacteria. Dietary patterns common in Western countries, particularly diets high in processed food and low in fiber, shift the microbiome in ways that may weaken immune tolerance. Certain intestinal infections, including those caused by Salmonella, Campylobacter, and specific strains of E. coli, have also been associated with increased IBD risk. None of these factors alone is sufficient to cause the disease, but in someone with the right genetic background, they can tip the balance.
Symptoms Beyond the Gut
The hallmark symptoms of IBD are persistent diarrhea, abdominal pain, bloody stool, fatigue, and unintended weight loss. But IBD is a systemic condition, meaning it affects far more than the intestines.
Joint problems are the most common issue outside the gut, affecting roughly 40% of people with IBD. These range from inflammation in the large joints of the knees and ankles to symmetric pain in the small joints of the hands. About 25% of IBD patients develop inflammation in the sacroiliac joints (where the spine meets the pelvis), and 5 to 10% develop ankylosing spondylitis, a form of inflammatory arthritis affecting the spine that causes morning stiffness and chronic low back pain.
Skin problems occur in up to 15% of patients, most often as tender, red-purple nodules on the shins or as deeper ulcerating sores called pyoderma gangrenosum. Eye inflammation affects 2 to 5% of patients and can cause redness, pain, light sensitivity, and blurred vision. Liver and bile duct complications show up in roughly half of IBD patients at some point during their illness, ranging from fatty liver disease to a more serious condition called primary sclerosing cholangitis that causes scarring of the bile ducts.
How IBD Is Diagnosed
Diagnosis usually involves a combination of blood tests, stool tests, and endoscopy (a procedure where a camera is used to look directly at the intestinal lining and take tissue samples). One of the most useful initial screening tools is a stool test that measures a protein called calprotectin, which is released by immune cells during intestinal inflammation.
A calprotectin level below 50 micrograms per gram generally rules out significant inflammation and makes IBD unlikely. Levels between 50 and 100 fall into a gray zone where monitoring is often sufficient; research from multiple centers has found that patients in this range rarely turn out to have IBD. Levels above 200 to 300 strongly suggest active intestinal inflammation and almost always lead to colonoscopy for a definitive diagnosis. The test is particularly valuable for distinguishing IBD from irritable bowel syndrome (IBS), which can cause similar symptoms like cramping and diarrhea but doesn’t involve visible inflammation.
Treatment Approaches
Treatment for IBD aims to calm active inflammation, heal the intestinal lining, and keep symptoms in remission for as long as possible. Mild cases may respond to anti-inflammatory medications taken by mouth or applied directly to the colon. Moderate to severe disease often requires medications that suppress the overactive immune response more broadly.
For people who don’t respond to standard therapies, biologic medications have transformed treatment over the past two decades. These are lab-made antibodies delivered by injection or infusion that target specific molecules driving inflammation. The three main classes work differently: one blocks a key inflammatory protein called TNF-alpha, another prevents immune cells from migrating into the gut wall, and the newest type blocks a pair of signaling molecules (interleukin-12 and interleukin-23) that drive the immune overreaction upstream. The choice depends on the type of IBD, its severity, and how a patient has responded to previous treatments.
Surgery remains part of the picture, particularly for Crohn’s disease, where roughly 8% of patients need an operation within the first year after diagnosis and about 19% within ten years. Rates have been declining as biologic therapies improve, but surgery is sometimes the best option for complications like strictures, fistulas, or sections of bowel that no longer respond to medication. For ulcerative colitis, removing the colon is considered curative since the disease is confined to that organ.
Diet and Day-to-Day Management
Diet doesn’t cause IBD, but it plays a real role in managing symptoms and, in some cases, reducing inflammation. The most studied dietary approach for Crohn’s disease is the Crohn’s Disease Exclusion Diet, which limits foods thought to damage the intestinal barrier (such as processed foods, certain additives, and animal fats) while emphasizing whole, unprocessed foods. In clinical trials, about 68 to 75% of patients on this diet achieved remission within six weeks, and 80% of those who responded maintained remission at six months.
A low-FODMAP diet, which reduces certain fermentable carbohydrates, helps about half of IBD patients manage symptoms like bloating and cramping. However, there is currently no evidence that it reduces intestinal inflammation itself. It’s best suited for people whose IBD is already in remission but who still experience irritable bowel-type symptoms on top of their disease.
Long-Term Colorectal Cancer Risk
Chronic intestinal inflammation increases the risk of colorectal cancer, and the risk climbs the longer you’ve had the disease. For ulcerative colitis, the incidence is about 2% at 10 years after diagnosis, 8% at 20 years, and 18% at 30 years. For Crohn’s disease affecting the colon, the numbers are somewhat lower: 2.9% at 10 years, 5.6% at 20 years, and 8.3% at 30 years. Because this risk rises substantially after the 8- to 10-year mark, regular surveillance colonoscopies become an important part of ongoing care at that point. Keeping inflammation well controlled with treatment also appears to reduce cancer risk over time.